United Therapeutics Corporation Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount
United Therapeutics Corporation (UTHR) reported Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount of -$41.60 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Income Taxes
us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount · last filed 2026-02-25
- United Therapeutics Corporation effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2025 was -$41.60M.
- United Therapeutics Corporation effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2024 was -$27.10M.
- United Therapeutics Corporation effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2023 was -$17.70M.
- United Therapeutics Corporation effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2022 was -$15.10M.
| Period end | Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount 12 month | Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$41.60M 10-K · filed 2026-02-25 | |
| 2024-12-31 | -$27.10M 10-K · filed 2026-02-25 | -$26.60M 10-K · filed 2025-02-26 |
| 2023-12-31 | -$17.70M 10-K · filed 2026-02-25 | -$17.30M 10-K · filed 2024-02-21 |
| 2022-12-31 | -$15.10M 10-K · filed 2025-02-26 | |
| 2021-12-31 | -$3.60M 10-K · filed 2024-02-21 | |
| 2020-12-31 | -$1.40M 10-K · filed 2023-02-22 | |
| 2019-12-31 | -$300.00K 10-K · filed 2020-02-26 | |
| 2018-12-31 | -$1.90M 10-K · filed 2020-02-26 | |
| 2017-12-31 | -$4.50M 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |